Hypertension in pregnancy: diagnosis and management
KEYWORDS: women, hypertension, pre-eclampsia, pregnancy, treatment, birth, committee, recommendations, antihypertensive, amended, risk, blood, evidence, care, gestational

offering aspirin to women with chronic hypertension who are pregnant are standard care, so these recommendations are not expected to change practice significantly. Return to recommendations Monitoring and treatment of gestational hypertension Recommendations 1.4.3 and 1.4.4 Why the committee made the recommendations The committee updated the table from the previous guideline on the management of pregnancy with gestational hypertension. There was very little evidence available on treatment initiation thresholds for gestational hypertension in pregnancy, so the committee made recommendations using the values specified in the recent Control of Hypertension in Pregnancy Study (CHIPS). There was evidence for target blood pressure levels from the large CHIPS trial, so the committee made recommendations based on this. The committee made a new recommendation referring to the NICE diagnostics guidance on placental growth factor (PLGF) testing as this is applicable to women with gestational hypertension. The committee were aware of the link between gestational hypertension and both pre- existing and gestational diabetes, therefore they made an overarching recommendation at the beginning of the guideline to cross-refer to the existing NICE guideline on diabetes in pregnancy. There was no evidence on fetal monitoring in gestational hypertension, so the committee made a research recommendation on the
